[
  {
    "title": "悦康药业(688658.SH)：YKYY017雾化吸入剂取得用于预防新型冠状病毒感染临床试验批件",
    "href": "http://stock.jrj.com.cn/2022/12/26165037238360.shtml",
    "datetime": "2022-12-26 16:50:59",
    "code": "688658"
  },
  {
    "title": "悦康药业：公司YKYY017雾化吸入剂取得用于预防新型冠状病毒感染临床试验批件",
    "href": "http://stock.jrj.com.cn/2022/12/26164737238283.shtml",
    "datetime": "2022-12-26 16:47:39",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658.SH)：270万股限售股将于12月26日解禁",
    "href": "http://stock.jrj.com.cn/2022/12/16173237218611.shtml",
    "datetime": "2022-12-16 17:32:30",
    "code": "688658"
  },
  {
    "title": "A股异动丨悦康药业(688658.SH)涨停 YKYY017雾化吸入剂获批开展临床试验",
    "href": "http://stock.jrj.com.cn/2022/12/01092837180331.shtml",
    "datetime": "2022-12-01 09:28:20",
    "code": "688658"
  },
  {
    "title": "悦康药业：YKYY017雾化吸入剂获批开展临床试验",
    "href": "http://stock.jrj.com.cn/2022/11/30155837178093.shtml",
    "datetime": "2022-11-30 15:58:45",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658.SH)：YKYY017雾化吸入剂获批开展临床试验",
    "href": "http://stock.jrj.com.cn/2022/11/30155137178118.shtml",
    "datetime": "2022-11-30 15:51:02",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658.SH)：惟精昫竔、焓湜枫德合计减持1648.47万股 减持计划尚未实施完毕",
    "href": "http://stock.jrj.com.cn/2022/11/20155337152384.shtml",
    "datetime": "2022-11-20 15:53:22",
    "code": "688658"
  },
  {
    "title": "悦康药业：注射用奥美拉唑钠通过仿制药一致性评价",
    "href": "http://stock.jrj.com.cn/2022/09/22153937014040.shtml",
    "datetime": "2022-09-22 15:39:26",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658.SH)：注射用奥美拉唑钠通过一致性评价",
    "href": "http://stock.jrj.com.cn/2022/09/22153737014047.shtml",
    "datetime": "2022-09-22 15:37:36",
    "code": "688658"
  },
  {
    "title": "悦康药业获得多肽药物发明专利证书",
    "href": "http://stock.jrj.com.cn/2022/09/08141636983007.shtml",
    "datetime": "2022-09-08 14:16:56",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658.SH)：惟精昫竔及其一致行动人合计持股比例减至6.86%",
    "href": "http://stock.jrj.com.cn/2022/09/07180936980838.shtml",
    "datetime": "2022-09-07 18:09:40",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658.SH)：获得1项多肽药物发明专利",
    "href": "http://stock.jrj.com.cn/2022/09/07180736980845.shtml",
    "datetime": "2022-09-07 18:07:38",
    "code": "688658"
  },
  {
    "title": "悦康药业披露2022年半年报 实现营收19.29亿元",
    "href": "http://stock.jrj.com.cn/2022/08/26091436939094.shtml",
    "datetime": "2022-08-26 09:14:02",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658.SH)半年度净利润1.40亿元、同比下降34.11%",
    "href": "http://stock.jrj.com.cn/2022/08/25214636937567.shtml",
    "datetime": "2022-08-25 21:46:38",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658.SH)：注射用阿奇霉素(0.5g)通过仿制药一致性评价",
    "href": "http://stock.jrj.com.cn/2022/08/03172736867182.shtml",
    "datetime": "2022-08-03 17:27:12",
    "code": "688658"
  },
  {
    "title": "A股异动 | 悦康药业(688658.SH)跌超5% 惟精昫竔、焓湜枫德拟减持合计不超7.42%股份",
    "href": "http://stock.jrj.com.cn/2022/07/28112736849773.shtml",
    "datetime": "2022-07-28 11:27:07",
    "code": "688658"
  },
  {
    "title": "A股异动 | 悦康药业(688658.SH)跌4.7% 股东拟合计减持不超7.42%股份",
    "href": "http://stock.jrj.com.cn/2022/07/28101536849530.shtml",
    "datetime": "2022-07-28 10:15:31",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658)：股东减持股份计划",
    "href": "http://stock.jrj.com.cn/2022/07/28093436849400.shtml",
    "datetime": "2022-07-28 09:34:29",
    "code": "688658"
  },
  {
    "title": "悦康药业：股东拟合计减持不超7.42%股份",
    "href": "http://stock.jrj.com.cn/2022/07/27202236848129.shtml",
    "datetime": "2022-07-27 20:22:55",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658.SH)：惟精昫竔、焓湜枫德拟减持合计不超7.42%股份",
    "href": "http://stock.jrj.com.cn/2022/07/27200936848050.shtml",
    "datetime": "2022-07-27 20:09:19",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658)：持股5%以上股东集中竞价减持计划时间届满暨减持结果",
    "href": "http://stock.jrj.com.cn/2022/07/25093836838956.shtml",
    "datetime": "2022-07-25 09:38:53",
    "code": "688658"
  },
  {
    "title": "悦康药业2名股东减持200万股 套现6008.2万 2022年第一季度公司净利6346.77万",
    "href": "http://stock.jrj.com.cn/2022/07/22225236837234.shtml",
    "datetime": "2022-07-22 22:52:13",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658.SH)：减持期届满 惟精昫竔、焓湜枫德累计减持共200万股",
    "href": "http://stock.jrj.com.cn/2022/07/22191736836686.shtml",
    "datetime": "2022-07-22 19:17:35",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658)：2021年年度权益分派实施，每10股派发现金红利6.8元（含税）",
    "href": "http://stock.jrj.com.cn/2022/07/08092836793352.shtml",
    "datetime": "2022-07-08 09:28:47",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658.SH)：代理进口产品注射用头孢呋辛钠(明可欣)通过仿制药一致性评价",
    "href": "http://stock.jrj.com.cn/2022/06/16171136735039.shtml",
    "datetime": "2022-06-16 17:11:41",
    "code": "688658"
  },
  {
    "title": "悦康药业（688658）：于悦康药业集团会议室举行投资者关系活动",
    "href": "http://stock.jrj.com.cn/2022/05/13153936646400.shtml",
    "datetime": "2022-05-13 15:39:42",
    "code": "688658"
  },
  {
    "title": "悦康药业2021年净利5.45亿同比增长23.34% 董事长于伟仕薪酬128万",
    "href": "http://stock.jrj.com.cn/2022/05/04155036556870.shtml",
    "datetime": "2022-05-04 15:50:57",
    "code": "688658"
  },
  {
    "title": "悦康药业披露2021年年报 实现营收49.66亿元",
    "href": "http://stock.jrj.com.cn/2022/04/29090336500717.shtml",
    "datetime": "2022-04-29 09:03:47",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658.SH)：子公司获得核酸药物递送系统发明专利",
    "href": "http://stock.jrj.com.cn/2022/04/22174336429913.shtml",
    "datetime": "2022-04-22 17:43:30",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658.SH)：拟使用不超10亿元闲置募集资金进行现金管理",
    "href": "http://stock.jrj.com.cn/2022/03/23184034871010.shtml",
    "datetime": "2022-03-23 18:40:28",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658.SH)：拟使用最高不超10亿元闲置自有资金进行现金管理",
    "href": "http://stock.jrj.com.cn/2022/03/23183834870714.shtml",
    "datetime": "2022-03-23 18:38:52",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658.SH)：注射用兰索拉唑通过仿制药一致性评价",
    "href": "http://stock.jrj.com.cn/2022/03/23183734870717.shtml",
    "datetime": "2022-03-23 18:37:30",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658.SH)：子公司注射用CT102获得核酸药物IIa期临床试验伦理审查批件",
    "href": "http://stock.jrj.com.cn/2022/03/11175834814750.shtml",
    "datetime": "2022-03-11 17:58:06",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658.SH)：注射用盐酸头孢吡肟(0.5g、1.0g)通过仿制药一致性评价",
    "href": "http://stock.jrj.com.cn/2022/03/09181034579111.shtml",
    "datetime": "2022-03-09 18:10:52",
    "code": "688658"
  },
  {
    "title": "悦康药业2021年净利5.63亿 同比增加27% 加大核心产品推广力度",
    "href": "http://stock.jrj.com.cn/2022/02/24205234453393.shtml",
    "datetime": "2022-02-24 20:52:06",
    "code": "688658"
  },
  {
    "title": "A股异动 | 悦康药业高开11% 与病原所合作开发广谱冠状病毒膜融合抑制剂多肽药物",
    "href": "http://stock.jrj.com.cn/2022/01/10093134139695.shtml",
    "datetime": "2022-01-10 09:31:34",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658.SH)：向激励对象首次授予1051.9万股限制性股票",
    "href": "http://stock.jrj.com.cn/2022/01/09162834137473.shtml",
    "datetime": "2022-01-09 16:28:23",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658.SH)：与病原所合作开发广谱冠状病毒膜融合抑制剂多肽药物",
    "href": "http://stock.jrj.com.cn/2022/01/09162634137472.shtml",
    "datetime": "2022-01-09 16:26:26",
    "code": "688658"
  },
  {
    "title": "悦康药业：与病原所签署《技术转让（专利权）合同》",
    "href": "http://stock.jrj.com.cn/2022/01/09153934137381.shtml",
    "datetime": "2022-01-09 15:39:51",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658.SH)：注射用头孢他啶通过仿制药一致性评价",
    "href": "http://stock.jrj.com.cn/2022/01/06171534129980.shtml",
    "datetime": "2022-01-06 17:15:11",
    "code": "688658"
  },
  {
    "title": "悦康药业年末股价创全年最高 两大重要股东拟减持7.87%股份",
    "href": "http://stock.jrj.com.cn/2022/01/05142634123552.shtml",
    "datetime": "2022-01-05 14:26:04",
    "code": "688658"
  },
  {
    "title": "A股异动 | 悦康药业(688658.SH)跌6% 股东拟合计减持不超7.87%股份",
    "href": "http://stock.jrj.com.cn/2022/01/04094534120077.shtml",
    "datetime": "2022-01-04 09:45:44",
    "code": "688658"
  },
  {
    "title": "悦康药业：惟精昫竔及其一致人拟合计减持不超7.87%股份",
    "href": "http://stock.jrj.com.cn/2022/01/03164134109944.shtml",
    "datetime": "2022-01-03 16:41:48",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658.SH)：惟精昫竔、焓湜枫德拟合计减持不超7.87%股份",
    "href": "http://stock.jrj.com.cn/2022/01/03160634109822.shtml",
    "datetime": "2022-01-03 16:06:54",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658.SH)：枸橼酸爱地那非片获批上市",
    "href": "http://stock.jrj.com.cn/2021/12/29142434080818.shtml",
    "datetime": "2021-12-29 14:24:39",
    "code": "688658"
  },
  {
    "title": "悦康药业新药“爱力士”取得《药品注册证书》：该产品2020 年市场规模为36亿",
    "href": "http://stock.jrj.com.cn/2021/12/29133234080654.shtml",
    "datetime": "2021-12-29 13:32:46",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658.SH)：董事、总经理于飞之配偶短线交易及致歉",
    "href": "http://stock.jrj.com.cn/2021/12/27172234071307.shtml",
    "datetime": "2021-12-27 17:22:51",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658.SH)：1.15亿股限售股将于12月24日解禁上市",
    "href": "http://stock.jrj.com.cn/2021/12/16164634024627.shtml",
    "datetime": "2021-12-16 16:46:43",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658.SH)：注射用头孢曲松钠通过仿制药一致性评价",
    "href": "http://stock.jrj.com.cn/2021/12/10174033995164.shtml",
    "datetime": "2021-12-10 17:40:03",
    "code": "688658"
  },
  {
    "title": "悦康药业聘任张伟为副总经理 第三季度公司净利1.61亿",
    "href": "http://stock.jrj.com.cn/2021/12/01211133951695.shtml",
    "datetime": "2021-12-01 21:11:07",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658.SH)：拟推1300万股的2021年限制性股票激励计划",
    "href": "http://stock.jrj.com.cn/2021/12/01180333950711.shtml",
    "datetime": "2021-12-01 18:03:45",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658.SH)第三季度净利润1.61亿元 同比增长31.92%",
    "href": "http://stock.jrj.com.cn/2021/10/28175733770400.shtml",
    "datetime": "2021-10-28 17:57:51",
    "code": "688658"
  },
  {
    "title": "悦康药业披露2021年三季报，前三季实现营收33.45亿元",
    "href": "http://stock.jrj.com.cn/2021/10/28174833770336.shtml",
    "datetime": "2021-10-28 17:48:34",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658.SH)：拟使用1.8亿元超募资金用于小核酸药物小试及中试平台项目",
    "href": "http://stock.jrj.com.cn/2021/09/22185933499873.shtml",
    "datetime": "2021-09-22 18:59:46",
    "code": "688658"
  },
  {
    "title": "悦康药业2021年半年度净利2.13亿元 同比净利增加61.01%",
    "href": "http://stock.jrj.com.cn/2021/08/25183033317840.shtml",
    "datetime": "2021-08-25 18:30:50",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658.SH)：上半年净利增61.01%至2.13亿元",
    "href": "http://stock.jrj.com.cn/2021/08/25174233317467.shtml",
    "datetime": "2021-08-25 17:42:12",
    "code": "688658"
  },
  {
    "title": "悦康药业核心技术人员朱丽辞职：工资低未持股 其他四名核心人才待遇类似",
    "href": "http://stock.jrj.com.cn/2021/08/05134433206427.shtml",
    "datetime": "2021-08-05 13:44:20",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658.SH)：核心技术人员朱丽离职",
    "href": "http://stock.jrj.com.cn/2021/08/04173233201932.shtml",
    "datetime": "2021-08-04 17:32:00",
    "code": "688658"
  },
  {
    "title": "悦康药业：“原料药+制剂”一体化控制成本提高 产品质量",
    "href": "http://stock.jrj.com.cn/2021/06/17220232950242.shtml",
    "datetime": "2021-06-17 22:02:29",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658.SH)：约436.54万股首发限售股6月24日解禁",
    "href": "http://stock.jrj.com.cn/2021/06/16190332941904.shtml",
    "datetime": "2021-06-16 19:03:02",
    "code": "688658"
  },
  {
    "title": "悦康药业：目前公司醋酸奥曲肽缓释微球产品正在药学研发阶段",
    "href": "http://stock.jrj.com.cn/2021/06/08110032892279.shtml",
    "datetime": "2021-06-08 11:00:00",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658.SH)：一季度净利升93.51%至7019.23万元",
    "href": "http://stock.jrj.com.cn/2021/04/28160232471840.shtml",
    "datetime": "2021-04-28 16:02:21",
    "code": "688658"
  },
  {
    "title": "悦康药业2020年净利增长54.89% 董事长于伟仕薪酬50万",
    "href": "http://stock.jrj.com.cn/2021/04/16113132385346.shtml",
    "datetime": "2021-04-16 11:31:24",
    "code": "688658"
  },
  {
    "title": "悦康药业去年赚4.42亿 拟派现2.03亿元",
    "href": "http://stock.jrj.com.cn/2021/04/16105232385089.shtml",
    "datetime": "2021-04-16 10:52:10",
    "code": "688658"
  },
  {
    "title": "悦康药业2020年度净利4.42亿增长54.85% 主要产品市场销量增加",
    "href": "http://stock.jrj.com.cn/2021/02/26195132034904.shtml",
    "datetime": "2021-02-26 19:51:27",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658.SH)业绩快报：2020年度净利升54.85%至4.42亿元",
    "href": "http://stock.jrj.com.cn/2021/02/26165532033533.shtml",
    "datetime": "2021-02-26 16:55:57",
    "code": "688658"
  },
  {
    "title": "悦康药业：阿莫西林胶囊通过仿制药一致性评价",
    "href": "http://stock.jrj.com.cn/2021/02/08091531868109.shtml",
    "datetime": "2021-02-08 09:15:49",
    "code": "688658"
  },
  {
    "title": "悦康药业拟以2100万元收购天龙药业100%股权，开展核酸药物新业务",
    "href": "http://stock.jrj.com.cn/2021/02/07131431860582.shtml",
    "datetime": "2021-02-07 13:14:27",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658.SH)：拟收购天龙药业100%股权",
    "href": "http://stock.jrj.com.cn/2021/02/05183531855707.shtml",
    "datetime": "2021-02-05 18:35:03",
    "code": "688658"
  },
  {
    "title": "悦康药业2020年预计净利4.2亿-4.5亿同比增长47.13%-57.64% 主要产品市场销量增加",
    "href": "http://stock.jrj.com.cn/2021/01/28230131803812.shtml",
    "datetime": "2021-01-28 23:01:00",
    "code": "688658"
  },
  {
    "title": "悦康药业：公司重点在研项目1类新药枸橼酸爱地那非研发项目目前处于CDE技术审评阶段",
    "href": "http://stock.jrj.com.cn/2021/01/11184731671617.shtml",
    "datetime": "2021-01-11 18:47:36",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658.SH)：盐酸二甲双胍片(0.25g)通过仿制药一致性评价",
    "href": "http://stock.jrj.com.cn/2021/01/06161131641797.shtml",
    "datetime": "2021-01-06 16:11:10",
    "code": "688658"
  },
  {
    "title": "每日“药”闻|京津冀带量采购联盟成立；悦康药业科创板“遇冷”",
    "href": "http://stock.jrj.com.cn/2020/12/25094331567342.shtml",
    "datetime": "2020-12-25 09:43:00",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658.SH)：公司股票12月24日起上市交易",
    "href": "http://stock.jrj.com.cn/2020/12/22191831546908.shtml",
    "datetime": "2020-12-22 19:18:23",
    "code": "688658"
  },
  {
    "title": "科创板明冠新材、通源环境、悦康药业网上申购中签号出炉",
    "href": "http://stock.jrj.com.cn/ipo/2020/12/15202531496435.shtml",
    "datetime": "2020-12-15 20:25:25",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658.SH)：中信证券投资获配270万股 网上摇号中签号共5.166万个",
    "href": "http://stock.jrj.com.cn/2020/12/15191631496064.shtml",
    "datetime": "2020-12-15 19:16:02",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658.SH)：网上发行最终中签率为0.03644957%",
    "href": "http://stock.jrj.com.cn/2020/12/14212831489295.shtml",
    "datetime": "2020-12-14 21:28:49",
    "code": "688658"
  },
  {
    "title": "今日新股申购：明冠新材、悦康药业、通源环境",
    "href": "http://stock.jrj.com.cn/2020/12/14090131484556.shtml",
    "datetime": "2020-12-14 09:01:00",
    "code": "688658"
  },
  {
    "title": "明冠新材、悦康药业、通源环境12月14日申购",
    "href": "http://stock.jrj.com.cn/2020/12/12075431469508.shtml",
    "datetime": "2020-12-12 07:54:53",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658.SH)：发行价定为24.36元/股 12月14日申购",
    "href": "http://stock.jrj.com.cn/2020/12/10191731458679.shtml",
    "datetime": "2020-12-10 19:17:50",
    "code": "688658"
  },
  {
    "title": "悦康药业(688658.SH)：网上路演时间12月11日14：00-17：00",
    "href": "http://stock.jrj.com.cn/2020/12/09191231450753.shtml",
    "datetime": "2020-12-09 19:12:17",
    "code": "688658"
  },
  {
    "title": "悦康药业IPO：科创属性不足还涉嫌同门行贿",
    "href": "http://stock.jrj.com.cn/2020/12/07081031428595.shtml",
    "datetime": "2020-12-07 08:10:00",
    "code": "688658"
  },
  {
    "title": "悦康药业覆盖12个用药领域",
    "href": "http://stock.jrj.com.cn/2020/12/01133731384120.shtml",
    "datetime": "2020-12-01 13:37:42",
    "code": "688658"
  },
  {
    "title": "[悦康药业]踏上新起点,勇闯“无人区”——热烈庆祝悦康药业集团成立19周年",
    "href": "http://stock.jrj.com.cn/2020/10/18000031690810.shtml",
    "datetime": "2020-10-18 00:00:00",
    "code": "688658"
  },
  {
    "title": "研发费用率偏低 悦康药业拟募资15亿元冲刺科创板IPO | 产业新股",
    "href": "http://stock.jrj.com.cn/2020/09/16193030764086.shtml",
    "datetime": "2020-09-16 19:30:46",
    "code": "688658"
  },
  {
    "title": "[悦康药业]悦康药业集团再次入选中国医药工业百强、中国医药研发产品线最佳工业企业",
    "href": "http://stock.jrj.com.cn/2020/08/31000031690811.shtml",
    "datetime": "2020-08-31 00:00:00",
    "code": "688658"
  },
  {
    "title": "完成二轮问询 悦康药业称存在持续产生较高研发投入风险",
    "href": "http://stock.jrj.com.cn/2020/08/27075830601114.shtml",
    "datetime": "2020-08-27 07:58:00",
    "code": "688658"
  },
  {
    "title": "[悦康药业]闪耀全国药店周!悦康药业再揽多项大奖",
    "href": "http://stock.jrj.com.cn/2020/08/26000031690817.shtml",
    "datetime": "2020-08-26 00:00:00",
    "code": "688658"
  },
  {
    "title": "悦康药业冲击科创板：本科及以上学历员工不足2成 研发费用率毛利率垫底",
    "href": "http://stock.jrj.com.cn/2020/05/13093829658095.shtml",
    "datetime": "2020-05-13 09:38:00",
    "code": "688658"
  },
  {
    "title": "[悦康药业]一类新药“注射用羟基红花黄色素A”临床方案 专家研讨会顺利召开",
    "href": "http://stock.jrj.com.cn/2020/05/10000031690814.shtml",
    "datetime": "2020-05-10 00:00:00",
    "code": "688658"
  },
  {
    "title": "[悦康药业]悦康药业集团入选国家企业技术中心",
    "href": "http://stock.jrj.com.cn/2020/03/12000031690813.shtml",
    "datetime": "2020-03-12 00:00:00",
    "code": "688658"
  },
  {
    "title": "[悦康药业]悦康药业集团2019年度总结表彰暨客户答谢会隆重举行",
    "href": "http://stock.jrj.com.cn/2020/01/14000031690803.shtml",
    "datetime": "2020-01-14 00:00:00",
    "code": "688658"
  },
  {
    "title": "[悦康药业]院士助力!《银杏叶提取物注射液临床应用中国专家共识》隆重发布",
    "href": "http://stock.jrj.com.cn/2019/12/06000031690804.shtml",
    "datetime": "2019-12-06 00:00:00",
    "code": "688658"
  },
  {
    "title": "[悦康药业]化解舆情是企业必须学会的一门功课",
    "href": "http://stock.jrj.com.cn/2019/09/16000031690793.shtml",
    "datetime": "2019-09-16 00:00:00",
    "code": "688658"
  },
  {
    "title": "[悦康药业]悦康盐酸二甲双胍缓释片同时通过改工艺和一致性评价",
    "href": "http://stock.jrj.com.cn/2018/12/22000031690808.shtml",
    "datetime": "2018-12-22 00:00:00",
    "code": "688658"
  },
  {
    "title": "[悦康药业]悦康药业等13家药企入选工信部绿色工厂示范单位",
    "href": "http://stock.jrj.com.cn/2018/12/14000031690807.shtml",
    "datetime": "2018-12-14 00:00:00",
    "code": "688658"
  },
  {
    "title": "[悦康药业]工业和信息化部王江平副部长调研悦康集团并组织行业座谈",
    "href": "http://stock.jrj.com.cn/2018/08/30000031690806.shtml",
    "datetime": "2018-08-30 00:00:00",
    "code": "688658"
  },
  {
    "title": "[悦康药业]悦康通银杏叶提取物注射液文献资料(点击可下载)",
    "href": "http://stock.jrj.com.cn/2018/08/24000031690828.shtml",
    "datetime": "2018-08-24 00:00:00",
    "code": "688658"
  },
  {
    "title": "[悦康药业]悦康药业集团再次入选中国医药工业百强",
    "href": "http://stock.jrj.com.cn/2018/08/06000031690827.shtml",
    "datetime": "2018-08-06 00:00:00",
    "code": "688658"
  },
  {
    "title": "[悦康药业]国家发改委高技术司领导莅临悦康调研指导",
    "href": "http://stock.jrj.com.cn/2018/07/13000031690825.shtml",
    "datetime": "2018-07-13 00:00:00",
    "code": "688658"
  },
  {
    "title": "[悦康药业]热烈庆祝悦康集团合肥制药首次通过GMP认证",
    "href": "http://stock.jrj.com.cn/2018/07/06000031690826.shtml",
    "datetime": "2018-07-06 00:00:00",
    "code": "688658"
  },
  {
    "title": "[悦康药业]悦康药业建设数字化药品生产线,质量标准与国际接轨",
    "href": "http://stock.jrj.com.cn/2018/02/28000031690823.shtml",
    "datetime": "2018-02-28 00:00:00",
    "code": "688658"
  },
  {
    "title": "[悦康药业]悦康药业等13家药企入选工信部绿色工厂示范单位",
    "href": "http://stock.jrj.com.cn/2018/02/28000031690824.shtml",
    "datetime": "2018-02-28 00:00:00",
    "code": "688658"
  },
  {
    "title": "[悦康药业]广州悦康生物制药有限公司获评广东省工程技术研究中心",
    "href": "http://stock.jrj.com.cn/2017/12/20000031690822.shtml",
    "datetime": "2017-12-20 00:00:00",
    "code": "688658"
  },
  {
    "title": "[悦康药业]悦康药业获评“北京经开区智能制造试点示范企业”",
    "href": "http://stock.jrj.com.cn/2017/11/17000031690818.shtml",
    "datetime": "2017-11-17 00:00:00",
    "code": "688658"
  },
  {
    "title": "[悦康药业]中国科学院陈凯先院士一行莅临悦康参观指导",
    "href": "http://stock.jrj.com.cn/2017/11/17000031690820.shtml",
    "datetime": "2017-11-17 00:00:00",
    "code": "688658"
  },
  {
    "title": "[悦康药业]我集团荣获“2017中国化学制药行业工业企业综合实力百强”",
    "href": "http://stock.jrj.com.cn/2017/11/17000031690819.shtml",
    "datetime": "2017-11-17 00:00:00",
    "code": "688658"
  },
  {
    "title": "[悦康药业]悦康药业领航医药转型,铸就品牌力量",
    "href": "http://stock.jrj.com.cn/2017/11/10000031690821.shtml",
    "datetime": "2017-11-10 00:00:00",
    "code": "688658"
  },
  {
    "title": "[悦康药业]悦康药业集团出席OSCG第十七届学术会议",
    "href": "http://stock.jrj.com.cn/2017/10/16000031690809.shtml",
    "datetime": "2017-10-16 00:00:00",
    "code": "688658"
  },
  {
    "title": "[悦康药业]悦康药业集团被评选为2017全国“质量标杆”",
    "href": "http://stock.jrj.com.cn/2017/09/06000031690796.shtml",
    "datetime": "2017-09-06 00:00:00",
    "code": "688658"
  },
  {
    "title": "[悦康药业]热烈祝贺悦康药业集团再次入围中国医药工业百强",
    "href": "http://stock.jrj.com.cn/2017/09/04000031690800.shtml",
    "datetime": "2017-09-04 00:00:00",
    "code": "688658"
  },
  {
    "title": "[悦康药业]悦康药业作为中国杰出企业代表参加西普会",
    "href": "http://stock.jrj.com.cn/2017/09/01000031690792.shtml",
    "datetime": "2017-09-01 00:00:00",
    "code": "688658"
  },
  {
    "title": "[悦康药业]于伟仕董事长出席毕井泉局长北京调研座谈会",
    "href": "http://stock.jrj.com.cn/2017/08/08000031690794.shtml",
    "datetime": "2017-08-08 00:00:00",
    "code": "688658"
  },
  {
    "title": "[悦康药业]悦康药业再登2016中国制药工业百强榜",
    "href": "http://stock.jrj.com.cn/2017/07/06000031690797.shtml",
    "datetime": "2017-07-06 00:00:00",
    "code": "688658"
  },
  {
    "title": "[悦康药业]我集团入选2016年中关村商标品牌示范培育单位",
    "href": "http://stock.jrj.com.cn/2017/04/28000031690798.shtml",
    "datetime": "2017-04-28 00:00:00",
    "code": "688658"
  },
  {
    "title": "[悦康药业]悦康药业集团出席中国医保商会六届六次理事会暨六届九次常务理事会",
    "href": "http://stock.jrj.com.cn/2017/03/20000031690790.shtml",
    "datetime": "2017-03-20 00:00:00",
    "code": "688658"
  },
  {
    "title": "[悦康药业]“不忘初心,砥砺前行”悦康药业集团2016年度表彰总结暨客户答谢会圆满落幕",
    "href": "http://stock.jrj.com.cn/2017/01/10000031690789.shtml",
    "datetime": "2017-01-10 00:00:00",
    "code": "688658"
  },
  {
    "title": "[悦康药业]北京院市合作协同创新联盟成立大会顺利召开",
    "href": "http://stock.jrj.com.cn/2017/01/03000031690799.shtml",
    "datetime": "2017-01-03 00:00:00",
    "code": "688658"
  }
]